Benzinga | Feb 23, 2021 04:06PM EST

Jazz Pharmaceuticals Q4 Adj. EPS $4.00 Misses $4.20 Estimate, Sales $665.52M Beat $639.55M Estimate

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $4.00 per share which missed the analyst consensus estimate of $4.20 by 4.76 percent. This is a 9.5 percent decrease over earnings of $4.42 per share from the same period last year. The company reported quarterly sales of $665.52 million which beat the analyst consensus estimate of $639.55 million by 4.06 percent. This is a 14.40 percent increase over sales of $581.74 million the same period last year.